Key Takeaways:
Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) announced new Phase 3 data showing its drug vutrisiran provides a consistent clinical benefit for patients with the heart condition ATTR-CM, supporting its use as a first-line treatment for the progressive and fatal disease.
"These new HELIOS-B analyses show that the clinical benefits of vutrisiran were maintained across these clinically complex patient groups," said Scott Solomon, a professor of medicine at Harvard Medical School and a cardiologist at Brigham and Women's Hospital. "Taken together, these findings support the use of vutrisiran as a first-line treatment option for ATTR-CM across a broad range of patient populations."
The new analyses from the HELIOS-B study, presented at the Heart Failure 2026 congress, showed vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared with a placebo. The benefits held true even in high-risk patients, including the 65% of the study population with atrial fibrillation. The drug, which is designed to knock down the transthyretin (TTR) protein at its source, achieved an 87% reduction in TTR levels over two and a half years of treatment.
The data reinforces the drug's potential in a market with over 500,000 patients worldwide. A separate safety analysis covering more than 25,000 patient-years found that rates of ocular adverse events linked to vitamin A deficiency were low and similar to placebo, addressing a key concern for this class of RNAi therapies. Alnylam also announced a new observational study, DemonsTTRate, which will follow over 2,000 ATTR-CM patients for up to five years to gather real-world data.
The positive data further de-risks vutrisiran and strengthens its commercial prospects for Alnylam's RNAi platform. Investors will watch for regulatory filings and adoption trends as the company positions AMVUTTRA against existing treatments.
This article is for informational purposes only and does not constitute investment advice.
